Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/171086
Title: Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Author: Torres Martí, Antoni
Bassetti, Matteo
Welte, Tobias
Rivolo, Simone
Remak, Edit
Peral, Carmen
Charbonneau, Claudie
Hammond, Jennifer
Ansari, Wajeeha
Grau, Santiago
Keywords: Pneumònia adquirida a la comunitat
Antibiòtics
Community-acquired pneumonia
Antibiotics
Issue Date: 31-Oct-2019
Publisher: Taylor and Francis
Abstract: Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS).Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs. 7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature.Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.
Note: Reproducció del document publicat a: https://doi.org/10.1080/13696998.2019.1688819
It is part of: Journal of Media Economics, 2019, vol. 23, num. 2, p. 148-155
URI: http://hdl.handle.net/2445/171086
Related resource: https://doi.org/10.1080/13696998.2019.1688819
ISSN: 0899-7764
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
700167.pdf1.71 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.